Advanced Esophageal Cancer Clinical Trial
Official title:
Combination Therapy of Anti-MUC1 CAR T Cells and PD-1 Knockout Engineered T Cells for Advanced Esophageal Cancer
The study is to assess the safety and efficacy of the immunotherapies using anti-MUC1 CAR T cells and /or PD-1 knockout engineered T cells in the treatment of patients with advanced esophageal cancer.
This is a combined phase 1 and 2 clinical study. The aim of the study is to assess the safety and efficacy of the immunotherapies using anti- MUC1 CAR T cells alone, anti- MUC1 CAR T combining PD-1 knockout engineered T cells, and PD-1 knockout engineered T cell only in the treatment of patients with advanced esophageal cancer. The treatment outcomes from each group will be compared. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05425472 -
A Phase II Study of HR070803 in the Treatment of Advanced Esophageal Cancer
|
Phase 2 | |
Recruiting |
NCT05174156 -
Study on the Biomarker of First-line Immunotherapy Combined With Chemotherapy in Advanced Esophageal Cancer
|
Phase 2 | |
Completed |
NCT03691090 -
Study of SHR-1210 in Combination With Chemotherapy in Advanced Esophageal Cancer
|
Phase 3 |